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Ischemic and reperfusion complications take leading role in development internal organs different diseases as liver injury during surgical interventions with decreasing blood supply.
The possibility of direct and remote ischemic preconditioning simulation is an experimental pharmacology keystone.
The greatest interest among a number of substances for pharm modeling ischemic preconditioning, it is a recombinant human erythropoietin showed to be effective in protecting to myocardial and brain tissues ischemia/reperfusion injuries protection [4, 5] .
However data of human recombinant erythropoietin usage in liver ischemia/reperfusion correction are rather contradictory .
The goal of our investigation was to assess the influence of human recombinant erythropoietin different dosage on blood flow velocity as microcirculation changes evaluation screening method.
Materials and methods: 70 white (male and female) 280-300g rates were used. Animals were grouped in 7 sets by 10 rates each. I/R group: reperfusion 30 minutes followed by 30 minutes of ischemia. I/R+EPO in dose 5 IU/kg group: reperfusion 30 minutes followed by 30 minutes of ischemia pretreated with 5 Statistic analysis revealed no differences between groups with 200 and 500 IU/kg, moreover small distinctions between groups with 50 and 100 IU/kg were found and dose of 50 IU/kg we decided to use later as safer one. Histological examination showed complex of nonspecific changes caused by ischemic damage and characterized by portal vessels and sinusoids desolation combined with pronounced dystrophic, necrobiotic hepatocytes changes and microcirculation impairment (Fig. 1.) . Reperfusion injury appear as severe sinusoidal dilation with diapedetic bleeding increasing dystrophic and necrobiotic changes (Fig. 2.) .
Human recombinant erythropoietin injection (Epocrin) 50 IU/kg decreased hepatocelular damage and manifested in necrobiotic changes absence in late stages of 30 minute of ischemia and their small presence at 30 minute of reperfusion. It's characteristic in group with EPO to haven't microthrombosis and stromal leakage (Fig. 3, Fig. 4.) . Conclusion. Thereby the study found that the recombinant erythropoietin dose-dependently prevented the development of reactive hyperemia 15 minute reperfusion. Prekonditsionuyuschey optimal dose is 50 IU/kg. The positive effect of recombinant erythropoietin also confirmed by morphological study and is manifested in the absence of thrombosis and hemorrhage, minimum changes in the severity of necrobiotic a tsentrolobulyarnyh necrosis and venous plethora 
